CAG
MRNA icon

Csenge Advisory Group’s Moderna MRNA Stock Holding History

Csenge Advisory Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,228
Closed -$222K – 735
2023
Q4 		$222K Buy
+2,228
New +$187K 0.01% 602
2023
Q2 		– Sell
-1,858
Closed -$285K – 683
2023
Q1 		$285K Buy
1,858
+681
+58% +$112K 0.02% 482
2022
Q4 		$211K Buy
+1,177
New +$192K 0.02% 551
2022
Q2 		– Sell
-1,305
Closed -$225K – 644
2022
Q1 		$225K Buy
1,305
+382
+41% +$64.3K 0.02% 573
2021
Q4 		$217K Buy
923
+103
+13% +$30.1K 0.02% 514
2021
Q3 		$280K Sell
820
-103
-11% -$38K 0.02% 487
2021
Q2 		$217K Buy
+923
New +$165K 0.02% 517

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Csenge Advisory Group's MRNA Position: Q1 2024 in Review

Csenge Advisory Group sold out of Moderna (MRNA) in Q1 2024, closing a stake of 2,228 shares — an estimated $222K sold.

Csenge Advisory Group first reported a position in MRNA in Q2 2021 and held it in 7 quarters. The position peaked at $285K in Q1 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Csenge Advisory Group reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Csenge Advisory Group sold 2,228 Moderna shares in Q1 2024, an estimated $222K.
  • Csenge Advisory Group first reported a position in Moderna in Q2 2021 and held it in 7 quarters.
  • Csenge Advisory Group's Moderna position peaked at $285K in Q1 2023.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Csenge Advisory Group's 13F filing for Q1 2024, filed 3 May 2024.